• Lantheus Holdings, Inc. reported first-quarter 2026 results with sales of US$377.33 million and net income of US$118.42 million, reaffirming full-year 2026 revenue guidance of US$1.40 billion to US$1.45 billion.
• The company also highlighted upcoming ASCO 2026 presentations on its investigational therapy LNTH-2403 in relapsed/refractory osteosarcoma and real-world prostate cancer imaging data, underscoring how its pipeline and existing radiodiagnostics may influence future clinical practice.
• We will now examine how Lantheus’s ASCO 2026 data for LNTH-2403 and prostate imaging could reshape its existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Lantheus Holdings Investment Narrative Recap

To own Lantheus, you need to believe its prostate and neuroimaging platforms can offset pricing pressure and dependence on PYLARIFY while new products scale. The Q1 2026 beat and reaffirmed US$1.40 billion to US$1.45 billion revenue guidance support this case in the near term, but do not materially change the key short term catalyst around new product uptake or the central risk of continued price and reimbursement pressure in PSMA PET imaging.

The ASCO 2026 presentations on LNTH-2403 and real world piflufolastat F 18 use sit alongside recent regulatory wins such as the FDA approval of PYLARIFY TruVu, which is expected to be commercially available in Q4 2026. Together, these events frame how Lantheus’s prostate and oncology franchises could evolve from a single product story into a broader radiopharmaceutical platform, an important consideration for investors watching both growth catalysts and concentration risk.

Yet, while the headlines look reassuring, investors should be aware that pricing pressure in PSMA PET imaging and reimbursement shifts could still...

Lantheus Holdings' narrative projects $1.9 billion revenue and $431.2 million earnings by 2029. This requires 7.4% yearly revenue growth and about a $152.2 million earnings increase from $279.0 million.

Uncover how Lantheus Holdings' forecasts yield a $104.08 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Before this update, the most optimistic analysts were assuming revenue could reach about US$2.2 billion and earnings about US$780 million by 2029, which is far more bullish than consensus and leans on the idea that product innovation outpaces pricing and reimbursement risks like PSMA price compression and policy changes; this new ASCO and earnings news could either support or challenge those expectations, so you should compare these very different outlooks when forming your own view.

Explore 6 other fair value estimates on Lantheus Holdings - why the stock might be worth 21% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Lantheus Holdings research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Lantheus Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lantheus Holdings' overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.